CAR-T therapy tisagenlecleucel (formerly CTL019) has been approved by the TGA for use in paediatric and young adult patients up to 25 years of age with B-cell precursor acute lymphoblastic leukaemia (ALL). The therapy – marketed as Kymriah by Novartis – is approved for young patients with ALL that is refractory, in relapse post-transplant or ...
CAR-T therapy gets TGA approval for ALL and DLBCL
By Michael Woodhead
14 Jan 2019